HALOG (halcinonide) by PharmaIN is corticosteroid hormone receptor agonists [moa]. First approved in 1977.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
HALOG (halcinonide) is a potent topical corticosteroid approved in 1977 for inflammatory and pruritic dermatological conditions. It works by agonizing corticosteroid hormone receptors to reduce inflammation and immune response in the skin. The ointment formulation provides sustained delivery for moderate-to-severe dermatitis, psoriasis, and lichen planus.
Product is in advanced lifecycle stage with moderate competitive pressure (30/100), indicating team may be consolidating resources or transitioning to lifecycle management and generic transition planning.
Corticosteroid Hormone Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of the Role of Top-down Processes in Neuronal Reorganization and Recovery From Sensory Loss: an Exploratory Behavioral and Electroencephalographic Study in Cochlear-supported Deaf Patients
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
Development of Electroencephalography (EEG) and Magnetoencephalography (MEG) Source Reconstruction With Fast Multipole Method
Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)
Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions
Worked on HALOG at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HALOG offers limited career growth opportunities given its LOE-approaching lifecycle and absence of linked job postings. Roles on this product focus on defensive commercial strategies, generic transition management, and margin protection rather than launch excitement or expansion.